Imagabalin
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Imagabalin ( , ; developmental code name PD-0332334) was an investigational drug that acts as a ligand for the α 2 δ subunit of the voltage-dependent calcium channel, with some selectivity for the α 2 δ 1 subunit over α 2 δ 2 . It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.
Imagabalin ( , ; developmental code name PD-0332334) was an investigational drug that acts as a ligand for the α 2 δ subunit of the voltage-dependent calcium channel, with some selectivity for the α 2 δ 1 subunit over α 2 δ 2 . It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer. The drug is no longer under development.
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377082889 under CC BY-SA 4.0; modifications have been made.